A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Inclusion Criteria:

• Have histologically or cytologically confirmed adenocarcinoma of the colon orrectum. Participants must have recurrent, unresectable or metastatic disease

• Be diagnosed to have KRAS, NRAS, and BRAF wild-type (WT) tumor as determined bylocal testing

• Must agree to the submission of fresh or archival tumor tissue post-progression fromthe most recent therapy, if clinically feasible

• Have measurable disease according to RECIST v1.1

• Have an eastern cooperative oncology group (ECOG) performance status (PS) of 0 or 1

• Participant must have received 1 line of systemic therapy (fluoropyrimidine-basedand oxaliplatin-based) for metastatic colorectal cancer (mCRC), with documentedradiographic disease progression on or after this line of therapy

Exclusion Criteria:

• Has medical history of (noninfectious) interstitial lung disease (ILD) /pneumonitis/pulmonary fibrosis or has current ILD/pneumonitis/pulmonary fibrosis,or where suspected ILD/pneumonitis/pulmonary fibrosis cannot be ruled out by imagingat screening

• Has known allergies, hypersensitivity, or intolerance to excipients of any of thefollowing: amivantamab, cetuximab or bevacizumab or any component of FOLFIRI

• Has a prior or concurrent second malignancy other than the disease under study orone whose natural history or treatment is unlikely to interfere with any studyendpoints of safety or the efficacy of the study treatment(s)

• Participant with known mismatch repair deficiency (dMMR)/ high microsatelliteinstability (MSI-H) status who has not received immunotherapy treatments

• Participant with known human epidermal growth factor receptor 2 (HER2)-positive/amplified tumor

• Has prior exposure to irinotecan, any agents that target epidermal growth factorreceptor (EGFR) or mesenchymal epithelial transition (MET)